'Assessing QbTest Utility in ADHD' (AQUA) is an NIHR CLAHRC East Midlands trial with MindTech providing clinical leadership (PI: Prof Chris Hollis) and technological support. The project arose out of the MindTech partnership with the SME QbTech Ltd.
The aim is to assess in a randomised controlled trial (RCT) whether providing clinicians and patients with the results of an objective test of activity and attention (QbTest) leads to earlier correct diagnosis of Attention Deficit/Hyperactivity Disorder (ADHD). A secondary objective is to assess whether the QbTest leads to earlier optimisation of treatment and improved patient outcomes in ADHD in routine NHS settings.
See publications page for the published protocol in BMJ Open (Trial registration number NCT02209116).